Apotex Is Blocked On Canadian Abiraterone
Zytiga Prostate-Cancer Brand Protected Until 2027
Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.
You may also be interested in...
Having unsuccessfully asserted a patent under the previous legal framework in Canada does not preclude an originator from trying again following legislative amendments enacted in 2017, the country’s Federal Court of Appeal has ruled in a decision on Pfizer’s Nivestym filgrastim biosimilar.
The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed after generics entered the market in November last year.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.